21/10/2026
October is Breast Cancer Awareness Month, and Macquarie University’s Jenny Gilchrist is showing what clinician-led advocacy looks like.
When AstraZeneca announced it would withdraw Zoladex from the Australian market, Jenny pushed for an alternative. Zoladex is a monthly hormone-suppressing injection relied on by thousands of Australians with breast cancer. As of 1 October, an equivalent treatment called Triptorelin is available on the PBS at standard prices. This means there is no gap in care for people who need access to the drug.
“Because I’m working with patients every single day, I was able to recognise from a clinician perspective and also understand from a patient perspective, the impact that would have on them,” says Jenny.